B Group Inc. Takes Position in Zai Lab Limited (NASDAQ:ZLAB)

B Group Inc. bought a new stake in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 400,000 shares of the company's stock, valued at approximately $10,476,000. Zai Lab makes up about 6.4% of B Group Inc.'s portfolio, making the stock its 4th biggest position. B Group Inc. owned approximately 0.37% of Zai Lab as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZLAB. Pictet Asset Management Holding SA acquired a new stake in Zai Lab during the fourth quarter worth about $31,000. Barclays PLC raised its stake in shares of Zai Lab by 337.6% in the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock valued at $97,000 after acquiring an additional 2,856 shares during the period. US Bancorp DE boosted its position in Zai Lab by 1,671.9% during the 4th quarter. US Bancorp DE now owns 5,865 shares of the company's stock worth $154,000 after purchasing an additional 5,534 shares during the period. Townsquare Capital LLC purchased a new position in Zai Lab in the fourth quarter valued at about $243,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Zai Lab by 15.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company's stock worth $290,000 after buying an additional 1,502 shares during the period. Institutional investors and hedge funds own 41.65% of the company's stock.

Insider Buying and Selling

In other Zai Lab news, insider Frazor Titus Edmondson III sold 14,544 shares of the business's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $32.98, for a total transaction of $479,661.12. Following the completion of the transaction, the insider now directly owns 14,328 shares of the company's stock, valued at $472,537.44. The trade was a 50.37 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Rafael Amado sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $38.41, for a total transaction of $115,230.00. Following the completion of the sale, the insider now owns 30,834 shares in the company, valued at $1,184,333.94. The trade was a 8.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 138,744 shares of company stock valued at $4,685,294. Insiders own 13.88% of the company's stock.

Wall Street Analysts Forecast Growth

ZLAB has been the subject of a number of analyst reports. Bank of America restated a "neutral" rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, March 13th. Scotiabank initiated coverage on shares of Zai Lab in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a research report on Thursday, March 27th.

Zai Lab Trading Down 5.3 %

ZLAB stock traded down $1.80 during mid-day trading on Friday, hitting $32.00. 1,671,388 shares of the company were exchanged, compared to its average volume of 852,203. The firm has a fifty day simple moving average of $33.29 and a 200 day simple moving average of $29.47. The company has a market capitalization of $3.51 billion, a PE ratio of -11.55 and a beta of 1.09. Zai Lab Limited has a twelve month low of $15.65 and a twelve month high of $39.77.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The business had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million. As a group, sell-side analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current year.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.